{
    "doi": "https://doi.org/10.1182/blood.V122.21.5340.5340",
    "article_title": "Prognostic Impact Of Comorbidity In Multiple Myeloma ",
    "article_date": "November 15, 2013",
    "session_type": "651. Myeloma: Biology and Pathophysiology, excluding Therapy",
    "abstract_text": "Multiple myeloma (MM) is a heterogeneous disease. Evaluation of prognostic factors and risk stratification at diagnosis is necessary to compare outcome. Attempts have been made to apply a comorbidity score in the clinical sitting, but a standardized general approach is still lacking. We hypothesized that a comprehensive examination of every associated disease in a large cohort of patients could better highlight the prognostic impact of comorbidity in MM. All consecutive patients diagnosed in our institution, from 1993 to 2013, with symptomatic MM according to IMWG criteria were included in our population-based MM registry. Patients with plasma cell leukemia or with palliative management were excluded. Clinical variables analyzed were: age, sex, Durie-Salmon, International Scoring System (ISS), percentage of plasma cell in bone marrow by morphology (PC), serum creatinine (Cr) and estimated glomerular filtration rate according with Modification of Diet in Renal Disease (eGFR-MDRD). The following comorbodities were analysed: hypertension (HTA), diabetes (DM), obesity (OB) (body mass index > 30 Kg/m 2 ), hyperlipaemia (HL), prior malignancy (PM), hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), peptic ulcer (PU), thromboembolism (TE), renal transplant (RT), splenectomy (S), cutaneous disease (CD), amyloidosis (AM), heart disease (HD) (arrhythmia, congestive heart failure, coronary artery disease, other), lung disease (LD) (chronic obstructive pulmonary disease, asthma, other), liver disease (HE) (cirrhosis, non-alcoholic fatty liver disease, other), neurological disorder (ND), psychiatric disorder (PD) and rheumatologic disorder (RD). Kaplan-Meier method was used to estimate OS curves. Cox regression was used to determine the prognostic impact of each comorbidity in a univariate and multivariate model. 311 patients were eligible. Median age was 66 years (12-91), 148 men (47.6 %) and 163 women. Percentage of comorbidities was: HTA 45; OB 32.5; DM 20.4; HD 20.4; LD 15.2; PU 10; HL 9.7; ND 8; PM 7.8; PD 6.5; HBV 3.9; HE 3.9; TE 3.6; RD 3,5; AM 2.3; HCV 1.9; CD 1.6; S 1; RT 0.6; HIV 0.3. 63 patients (20.4 %) showed no comorbidities. Univariate analysis ( table 1 ) demonstrated that AM (P=0.022), HCV (0.038), HIV (0.022), PD (0.015) and ND (0.05) were significantly associated with shorter OS. The variables associated with mortality in the multivariate analysis were age (p=0.002), ISS (III vs I: p=0.01), PC (p=0.05) and Cr (p=0.02). Results will be validated in another MM series and presented during the meeting.  Comorbidity . Definition . N (%) . Median OS . HR (95% CI) . P- value . Hypertension -No -Yes 170 139 (45) 31 34 1,009 (0,764-1,332) 0,951 Diabetes -No -Yes 246 63 (20,4) 32 42 1,111 (0,794-1,554) 0,540 Obesity -No -Yes 164 79 (32,5) 49 36 1,226 (0,861-1,745) 0,258 Hyperlipaemia -No -Yes 279 30 (9,7) 32 47 0,723 (0,427-1,223) 0,227 Prior malignancy -No -Yes 285 24 (7,8) 34 29 1,172 (0,712-1,928) 0,533 HBV -No -Yes 297 12 (3,9) 32 NR 0,365 (0,117-1,142) 0,083 HCV -No -Yes 303 6 (1,9) 33 7 2,575 (1.053-6,294) 0.038  HIV -No -Yes 308 1 (0,3) 33 1 10,290 (1,402-75,542) 0,022  Peptic ulcer -No -Yes 278 31 (10) 32 40 0,971 (0,623-1,512) 0,895 Thromboembolism -No -Yes 298 11 (3,6) 33 33 1,777 (0,936-3,372) 0,079 Renal transplant -No -Yes 307 2 (0,6) 33 5 2,075 (0,288-14,934) 0,468 Splenectomy -No -Yes 306 3 (1) 33 29 1,559 0,386-6,302) 0,533 Cutaneous disease -No -Yes 304 5 (1,6) 33 67 0,598 (0,148-2,410) 0,470 Amyloidosis -No -Yes 303 7 (2,3) 34 13 2,428 (1,139-5,176) 0,022  Heart disease -No -Yes -Arrhythmia -CHF -CAD -Other 247 63 (20,4) 20 21 17 5 33 32 32 42 29 25 1,245 (0,898-1,727) 0,189 Lung disease -No -Yes -COPD -Astma -Other 262 47 (15,2) 27 146 32 33 31 52 33 1,075 (0,740-1,562) 0,702 Liver disease -No -Yes -Cirrhosis -NAFLD -Other 297 12 (3,9) 2 6 4 33 10 1 8 16 1,341 (0,709-2,536) 0,367 Neurological disorder -No -Yes 286 25 (8) 34 24 1,610 (0,989-2,621) 0,056  Psychiatric disorder -No -Yes 289 20 (6,5) 33 15 1,894 (1,130-3,176) 0,015  Rheumatologic disorder -No -Yes 300 11 (3,5) 33 88 0,702 (0,311-1,584) 0,394 Comorbidity . Definition . N (%) . Median OS . HR (95% CI) . P- value . Hypertension -No -Yes 170 139 (45) 31 34 1,009 (0,764-1,332) 0,951 Diabetes -No -Yes 246 63 (20,4) 32 42 1,111 (0,794-1,554) 0,540 Obesity -No -Yes 164 79 (32,5) 49 36 1,226 (0,861-1,745) 0,258 Hyperlipaemia -No -Yes 279 30 (9,7) 32 47 0,723 (0,427-1,223) 0,227 Prior malignancy -No -Yes 285 24 (7,8) 34 29 1,172 (0,712-1,928) 0,533 HBV -No -Yes 297 12 (3,9) 32 NR 0,365 (0,117-1,142) 0,083 HCV -No -Yes 303 6 (1,9) 33 7 2,575 (1.053-6,294) 0.038  HIV -No -Yes 308 1 (0,3) 33 1 10,290 (1,402-75,542) 0,022  Peptic ulcer -No -Yes 278 31 (10) 32 40 0,971 (0,623-1,512) 0,895 Thromboembolism -No -Yes 298 11 (3,6) 33 33 1,777 (0,936-3,372) 0,079 Renal transplant -No -Yes 307 2 (0,6) 33 5 2,075 (0,288-14,934) 0,468 Splenectomy -No -Yes 306 3 (1) 33 29 1,559 0,386-6,302) 0,533 Cutaneous disease -No -Yes 304 5 (1,6) 33 67 0,598 (0,148-2,410) 0,470 Amyloidosis -No -Yes 303 7 (2,3) 34 13 2,428 (1,139-5,176) 0,022  Heart disease -No -Yes -Arrhythmia -CHF -CAD -Other 247 63 (20,4) 20 21 17 5 33 32 32 42 29 25 1,245 (0,898-1,727) 0,189 Lung disease -No -Yes -COPD -Astma -Other 262 47 (15,2) 27 146 32 33 31 52 33 1,075 (0,740-1,562) 0,702 Liver disease -No -Yes -Cirrhosis -NAFLD -Other 297 12 (3,9) 2 6 4 33 10 1 8 16 1,341 (0,709-2,536) 0,367 Neurological disorder -No -Yes 286 25 (8) 34 24 1,610 (0,989-2,621) 0,056  Psychiatric disorder -No -Yes 289 20 (6,5) 33 15 1,894 (1,130-3,176) 0,015  Rheumatologic disorder -No -Yes 300 11 (3,5) 33 88 0,702 (0,311-1,584) 0,394 View Large The overall prognosis of MM depends on a variety of host and disease-related characteristics. We confirm age, ISS, PC and Cr as robust and independent prognostic factors. Adjusting for these factors, no isolated comorbidity reach statistical significance; however, comorbidity seems to have a role in MM prognosis. More studies are warranted to define the prognostic impact of comorbidities in MM. Disclosures: No relevant conflicts of interest to declare.",
    "topics": [
        "comorbidity",
        "multiple myeloma",
        "obesity",
        "amyloidosis",
        "asthma",
        "cancer",
        "cardiac arrhythmia",
        "chronic obstructive airway disease",
        "congestive heart failure",
        "diabetes mellitus"
    ],
    "author_names": [
        "Rafael R\u00edos Tamayo",
        "Joaqu\u00edn Mart\u00ednez L\u00f3pez",
        "Manuel Jurado",
        "Mar\u00eda Esther Clavero S\u00e1nchez",
        "F\u00e1tima L\u00f3pez Jim\u00e9nez",
        "Mar\u00eda Liz Paciello Coronel",
        "Jos\u00e9 Ram\u00f3n Garc\u00eda Fern\u00e1ndez",
        "Youssef Moatassim de la Torre",
        "Francisco L\u00f3pez Berenguel",
        "Rosario Leyva Ferrer",
        "Juan S\u00e1inz P\u00e9rez",
        "Elena Molina Portillo",
        "Mar\u00eda Jos\u00e9 S\u00e1nchez P\u00e9rez",
        "Jos\u00e9 Mar\u00eda de Pablos Gallego",
        "Pilar L\u00f3pez Garrido",
        "Jos\u00e9 Juan Jim\u00e9nez Mole\u00f3n",
        "Amaia L\u00f3pez de Lacalle",
        "Juan Jos\u00e9 Lahuerta Palacios"
    ],
    "author_dict_list": [
        {
            "author_name": "Rafael R\u00edos Tamayo",
            "author_affiliations": [
                "Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain, "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Joaqu\u00edn Mart\u00ednez L\u00f3pez",
            "author_affiliations": [
                "Servicio Hematolog\u00eda-Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Manuel Jurado",
            "author_affiliations": [
                "Servicio Hematolog\u00eda-Hemoterapia, Hospital Virgen de las Nieves, Granada, Spain, "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda Esther Clavero S\u00e1nchez",
            "author_affiliations": [
                "Hospital Santa Ana, Motril, Granada, Spain, "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "F\u00e1tima L\u00f3pez Jim\u00e9nez",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain, "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda Liz Paciello Coronel",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jos\u00e9 Ram\u00f3n Garc\u00eda Fern\u00e1ndez",
            "author_affiliations": [
                "Hospital de Baza, Baza, Granada, Spain, "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Youssef Moatassim de la Torre",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain, "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Francisco L\u00f3pez Berenguel",
            "author_affiliations": [
                "Hospital de Baza, Baza, Granada, Spain, "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rosario Leyva Ferrer",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain, "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan S\u00e1inz P\u00e9rez",
            "author_affiliations": [
                "Genomic Oncology Area, GENYO, Centre for Genomics and Oncological Research: Pfizer/University of Granada/Andalusian Regional Government, Granada, Spain, "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Elena Molina Portillo",
            "author_affiliations": [
                "Registro del C\u00e1ncer de Granada, Escuela Andaluza de Salud P\u00fablica, Granada, Espa\u00f1a. CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Granada, Spain, "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Mar\u00eda Jos\u00e9 S\u00e1nchez P\u00e9rez",
            "author_affiliations": [
                "Registro del C\u00e1ncer de Granada, Escuela Andaluza de Salud P\u00fablica, Granada, Espa\u00f1a. CIBER Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Granada, Spain, "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jos\u00e9 Mar\u00eda de Pablos Gallego",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain, "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pilar L\u00f3pez Garrido",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario Virgen de las Nieves, Granada, Spain, "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jos\u00e9 Juan Jim\u00e9nez Mole\u00f3n",
            "author_affiliations": [
                "Departamento de Medicina Preventiva y Salud P\u00fablica, Universidad de Granada, Granada, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Amaia L\u00f3pez de Lacalle",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Juan Jos\u00e9 Lahuerta Palacios",
            "author_affiliations": [
                "Servicio de Hematolog\u00eda-Hemoterapia, Hospital Universitario 12 de Octubre, Madrid, Spain, "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-27T18:43:55",
    "is_scraped": "1"
}